Jon Congleton - 13 Feb 2024 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role
Chief Executive Officer, Director
Signature
/s/ Adam Levy, Attorney-in-fact
Issuer symbol
MLYS
Transactions as of
13 Feb 2024
Net transactions value
$0
Form type
4
Filing time
15 Feb 2024, 16:26:00 UTC
Previous filing
27 Nov 2023
Next filing
14 Jun 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MLYS Stock Option Award $0 +425,000 $0.000000 425,000 13 Feb 2024 Common Stock 425,000 $14.25 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 25% of the total number of shares of Common Stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of Common Stock subject to the option on each monthly anniversary thereafter.